Macrogenics CEO Scott Koenig
September 7, 2021 05:29 PM EDT
R&D

Macro­Gen­ics flips over an OS dud for can­cer drug Mar­gen­za in sur­pris­ing turn­around from ear­li­er da­ta

Kyle Blankenship

Can­cer play­er Macro­Gen­ics scored a big win with its full ap­proval for an­ti-HER2 drug Mar­gen­za last win­ter based on a head-to-head matchup with breast can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times